# China NMPA Drug Inspection - Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. - Prepared licorice

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/9bc308cd-dd3a-4663-91bf-e1d9f6c8a6eb/
Source feed: China

> China NMPA drug inspection for Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. published July 09, 2018. Drug: Prepared licorice. The Chongqing Municipal Food and Drug Administration (MFA) released its 2018 No. 3 Drug Quality Announcement on July 9, 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Food and Drug Administration's Drug Quality Bulletin, Issue 3, 2018
- Company Name: Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-07-09
- Drug Name: Prepared licorice
- Inspection Finding: Non-compliant with regulations: [Content determination]
- Summary: The Chongqing Municipal Food and Drug Administration (MFA) released its 2018 No. 3 Drug Quality Announcement on July 9, 2018, detailing results from city-wide sampling inspections conducted throughout 2018. This regulatory action aimed to bolster drug quality oversight, maintain market integrity, and ensure public drug safety.

The announcement identified 11 batches of Traditional Chinese Medicine (TCM) pieces that failed to meet established quality standards. Manufacturers implicated include Anhui Fangshi Traditional Chinese Medicine Pieces Co., Ltd., Anhui Yishengtang Traditional Chinese Medicine Pieces Co., Ltd., Chengdu Jiankang Pharmaceutical Co., Ltd., Chengdu Kexin Pharmaceutical Co., Ltd., Sichuan Zining Traditional Chinese Medicine Pieces Co., Ltd., Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Longfa Pharmaceutical Co., Ltd., Chengdu Yicheng Pharmaceutical Co., Ltd., and Sichuan Kangquantang Traditional Chinese Medicine Pieces Co., Ltd.

Key violations concerned critical quality attributes such as "Properties," "Identification," "Microscopic Identification," "Extractives," and "Content Determination." These failures indicate non-compliance with the Chinese Pharmacopoeia (2010 and 2015 Editions, Part I), suggesting issues with product identity, purity, or strength. A notable concern was that some manufacturers denied producing the non-compliant batches, raising questions about supply chain accountability. Manufacturers are expected to implement corrective actions to address these deficiencies and ensure full compliance with regulatory standards.

Company: https://www.globalkeysolutions.net/companies/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/4f6f764d-7635-42f2-ab3f-4f79c6c03c0a/